EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Effect of early initiation of intravenous lipid administration on the incidence and severity of chronic lung disease in premature infants


Journal of Pediatrics 123(6): 975-982
Effect of early initiation of intravenous lipid administration on the incidence and severity of chronic lung disease in premature infants
Objective: To investigate whether intravenous administration of lipid nutrition (Intralipid) within 12 hours of birth to ventilator-dependent premature infants would decrease the incidence or severity, or both, of chronic lung disease. Method: We randomly assigned 133 infants to Intralipid or control groups, using two weight strata: 42 Intralipid versus 37 control subjects in the 600 to 800 gm stratum, and 28 Intralipid versus 26 control subjects in the 801 to 1000 gm stratum. The Intralipid group received 20% Intralipid at lt 12 hours after birth, starting at a dose of 0.5 gm/kg and increasing to a maximum of 1.5 gm/kg, maintained through day 7. Control infants received no lipid until after day 7. Neither group received enteral feedings until after day 7. Results: No significant differences in mortality rates were present in the total population (23/70 = 32.9% vs 16/63 = 25.4%; p = 0.35, Intralipid vs control); however, the mortality rate increased significantly in 600 to 800 gm Infants receiving Intralipid versus the control Infants (20/41 = 47.5% vs 9/37 = 24.3%; p = 0.032). No significant differences were found in the number of infants In whom chronic lung disease developed (requiring oxygen for gtoreq 28 days), proportion requiring oxygen for gtoreq 60 days, number of survivors without chronic lung disease, or total oxygen and ventilation requirements. However, 600 to 800 gm infants receiving Intralipid had significantly more pulmonary hemorrhage, and greater numbers of infants receiving Intralipid in both weight categories required supplemental oxygen at day 7. The incidence of other complications of prematurity, time required to regain birth weight, and duration of hospital stay did not differ between groups. Conclusion: Intralipid administration initiated at lt 12 hours after birth failed to protect very low birth weight premature infants from chronic lung disease. Some of the results raise questions about possible deleterious effects of Intralipid when administered early in the first week of life.

Accession: 002355305

PMID: 8229533

DOI: 10.1016/s0022-3476(05)80397-x

Download PDF Full Text: Effect of early initiation of intravenous lipid administration on the incidence and severity of chronic lung disease in premature infants



Related references

Effect of early vs late introduction of intravenous lipid to preterm infants on death and chronic lung disease Results of meta-analyses. Pediatric Research 43(4 PART 2): 214A, April, 1998

Early surfactant and dexamethasone therapy reduce the incidence of chronic lung disease in premature infants. Pediatric Research 37(4 PART 2): 357A, 1994

Evaluation of the severity of chronic lung disease in premature infants by pulse oximeter. Acta Paediatrica Taiwanica 45(3): 145-150, 2004

Randomised trial of effect of delayed intravenous lipid administration on chronic lung disease in preterm neonates. Journal of Pediatric Gastroenterology and Nutrition 22(3): 303-306, 1996

Reducing the incidence of chronic lung disease in very premature infants with aminophylline. International Journal of Preventive Medicine 5(5): 569-576, 2014

The effects of vitamin a therapy on the incidence of chronic lung disease cld in premature infants. Pediatric Research 27(4 PART 2): 296A, 1990

Increased aldehyde lipid peroxidation products in premature infants with chronic lung disease. Archives of Disease in Childhood. Fetal and Neonatal Edition 81(3): F235-F235, 2000

Intravenous administration of lipid emulsions to premature infants. Clinics in Perinatology 13(1): 133-162, 1986

Raised concentrations of aldehyde lipid peroxidation products in premature infants with chronic lung disease. Archives of Disease in Childhood. Fetal and Neonatal Edition 80(1): F21-F25, 1999

Prevention of chronic lung disease (CLD) in premature infants with early dexamethasone therapy. Pediatric Pulmonology. Supplement 16: 35-36, 1997